ClinicalTrials.gg
WithdrawnNCT07084909HARRIERUpdated Dec 10, 2025

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

A Phase 2/3 interventional study of piflufolastat F 18 in Clear Cell Renal Cell Carcinoma, sponsored by Lantheus Medical Imaging. Withdrawn at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 2/3, Interventional, and Diagnostic

Why this study was withdrawn
Operational challenges in patient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
984th of 1,008
0 · median 40
Started
2025
with 38 others
Phase 2/3
Only one
of the 1,142
Registered
1,086th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 984th largest by enrollment of the 1,008 interventional ones that give a count, is one of 39 that started in 2025, is the only one in phase 2/3, and was the 1,086th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.

The main questions it aims to answer are:

  • What is the most appropriate dose and scan timing window for piflufolastat F 18 PET/CT for patients with clear cell Renal Cell Carcinoma (ccRCC) with known metastatic disease?
  • Ability of piflufolastat F 18 PET/CT to detect metastatic of lesions ccRCC in patients with suspected metastatic disease and those at high risk for metastatic disease (the cancer has spread beyond the kidney) and impact of the imaging on clinical management of the kidney cancer?

Participants will:

  • Receive a single injection of piflufolastat F 18 injection followed by imaging scans.
  • Be contacted via telephone to ask about any reactions or discomforts they may have after the piflufolastat F 18 injection.
  • May be followed for up to 6 months to collect data about disease progression.
Read the detailed description

This is an adaptive Phase 2/3, open-label, multi-center, single-arm study designed to evaluate diagnostic performance of piflufolastat F 18 PET/CT in the staging of patients suspected of having, or who are at high risk for, metastatic ccRCC and its impact on intended clinical management.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma

Keywords

  • kidney cancer
  • renal cell carcinoma
  • clear cell
  • Piflufolastat F 18
  • PYLARIFY
  • imaging
  • ccRCC
  • PET/CT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients ≥18 years of age
  2. Patients must have the ability to understand and sign an approved form (ICF)
  3. Patients must have the ability to understand and comply with all protocol requirements.
  4. Subjects should satisfy the following criteria:

1) For the Phase 2 (dose optimization) portion of the study: ccRCC patients with at least one suspected lesion identified by conventional imaging scans at the time of enrolling in the study 2) For the Phase 3 portion of the study: Patients must be suspected of having or be at high risk for developing metastatic disease. This patient population is generally defined as one of the following:

  1. Newly diagnosed ccRCC patients or post- nephrectomy/post-partial nephrectomy patients with radiographically suspected ccRCC metastatic disease by conventional imaging (CI) planned for to confirm metastatic disease
  2. T2B-T4, N0, M0 as assessed by conventional imaging (CI) at initial staging pre-nephrectomy/pre-partial nephrectomy
  3. Confirmed ccRCC with high risk of metastatic recurrence post nephrectomy pT1b or higher with G3-4 N0( or pNX where clinically N0)M0. Patients must be N0, M0 on the follow up CI not more than 60 days prior to piflufolastat F18 scan
  4. Patients with new radiographically suspected oligometastatic ccRCC (up to 5 metastatic lesions at presentation) planned for nephrectomy or biopsy for lesion verification of at least one suspected metastatic lesion

    5. Completed staging evaluation with baseline conventional imaging (contrast-enhanced CT or contrast-enhanced MRI of the chest, abdomen, and pelvis, or skull base to mid thigh FDG PET)less than or equal to 60 days prior to piflufolastat F 18 PET/CT (Day 1). If baseline conventional imaging was performed outside of the 60-day window, it can be repeated during the screening period provided that there are at least 24 hours between conventional imaging and piflufolastat F 18 (Day 1). Conventional imaging must be available for central evaluation.

    6. Patients must have an (ECOG) performance status of 0 to 2.

    7. Patients with of at least 6 months as determined by the investigator or treating physician.

Exclusion criteria

Exclusion Criteria:

  1. Patients administered any high energy (>300 KeV) gamma-emitting radioisotope within five (5) physical half-lives, prior to Day 1.
  2. Known to the components of piflufolastat F 18 or its analogs.
  3. Pregnant or breastfeeding females. Pregnancy testing will be performed in potentially childbearing women prior to piflufolastat F 18 administration on Day 1.
  4. Prior imaging with girentuximab or any PSMA-PET agent or any non-approved ccRCC imaging agent within the last 3-months prior to piflufolastat F 18 PET/CT.
  5. Patients who are in active systemic therapy for ccRCC prior to piflufolastat F 18 PET/CT. 30-day (12 weeks for immunotherapy) is required from the last dose of systemic therapy to piflufolastat F18 administration.
  6. Patients who are expected to receive anti-cancer treatment between baseline conventional imaging, piflufolastat F 18 PET/CT, , or surgery.
  7. Evidence of any other active within the past 3 years, except non-melanoma skin cancer, carcinoma in situ, adequately treated Stage 1 cancer from which the patent is in remission and has been in remission for a minimum of 2 years. Any or maintenance systemic chemotherapy must have been completed at least 30 days prior to piflufolastat F 18 PET/CT administration (12-week washout if immunotherapy).
  8. Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study.
  9. Patients requiring dialysis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase 2 - Dose Optimization

    The dose-optimization, or Phase 2, part of the study will enroll 6-12 ccRCC patients, with at least one metastatic lesion identified by conventional imaging at the time of enrollment, to define the optimal dose and scan timing window for piflufolastat F18 PET/CT. Piflufolastat F18 will be administered at a target dose of 9 mCi \[+/-1 mCi\]) after which patients will be scanned at 60-90 minutes and again at 3-4 hours.

    Drug: piflufolastat F 18

  • Experimental
    Phase 3 - Single-arm Expansion

    Phase 3 will commence once the optimal dose and optimal timing window from Phase 2, dose optimization, are determined. Phase 3 will be a single-arm study that will enroll 274 patients with radiographically suspected metastatic disease by conventional imaging or at high risk for metastatic ccRCC at the time of enrollment.

    Drug: piflufolastat F 18

Interventions

  • 18F-DCFPyL is a fluorine-18 radiolabeled low molecular weight positron emission tomography (PET) tracer that binds to the extracellular domain of prostate-specific membrane antigen (PSMA) with high affinity.

    Also known as: PYLARIFY

06

What researchers measure

Primary outcomes

  1. Phase 2 Primary Objective - Establishing the optimum dose and timing window of piflufolastat F18 for detection of metastatic disease

    Defining the optimal dose and scan timing window for Piflufolastat F18 PET/CT

    Time frame: On Day 1 (day of injection) where Piflufolastat F18 will be administered at a target dose of 9 mCi [+/-1 mCi]) after which patients will be scanned at 60-90 minutes and again at 3-4 hours.

  2. Phase 3 Primary Objective - To assess the diagnostic performance of piflufolastat F 18 PET/CT to determine the presence or absence of metastatic disease in ccRCC patients.

    Sensitivity of piflufolastat F 18 PET/CT at the patient level to determine the presence of metastatic ccRCC relative to the composite truth standard. Specificity of piflufolastat F 18 PET/CT at the patient level to determine the absence of metastatic ccRCC relative to the composite truth standard.

    Time frame: From Day 1 (day of injection) where Piflufolastat F18 will be administered to 6 months post-piflufolastat F 18 administration to establish the standard of truth.

Secondary outcomes

  1. Phase 3 -To assess the diagnostic performance of piflufolastat F 18 PET/CT for identifying the presence of metastatic lesions in ccRCC

    Correct localization rate (CLR) at the patient level, defined as the percentage of patients for whom there is a one-to-one correspondence between localization of at least one lesion identified on piflufolastat F 18 PET CT and a composite standard of truth (SOT)

    Time frame: From Day 1 (day of injection) where Piflufolastat F18 will be administered to 6 months post-piflufolastat F 18 administration to establish the standard of truth.

  2. Phase 3 - Safety and Tolerability

    Incidence of adverse events (AEs), changes in vital signs, clinical laboratory parameters and concomitant medications.

    Time frame: From screening to to 6 months post-piflufolastat F 18 administration

  3. Phase 3 - Assess the impact of piflufolastat F 18 PET/CT on intended and actual patient clinical management

    Change in intended and actual patient clinical management in all patients as assessed by a Medical Management Questionnaire (MMQ)

    Time frame: From Day 1 (day of injection) where Piflufolastat F18 will be administered to 6 months post-piflufolastat F 18 administration

Other outcomes

  1. Exploratory - Assess the sensitivity of piflufolastat F 18 PET/CT at the Lesion Level

    Sensitivity of piflufolastat F 18 PET/CT at the lesion level to determine the presence of metastatic ccRCC relative to the composite truth standard, if possible

    Time frame: From screening to 6 months post-piflufolastat F 18 administration

  2. Exploratory - Measure PSMA expression and neovascular localization in metastatic lesions using immunohistochemistry (IHC)

    Use of IHC to assess PSMA expression and neovascular localization. Biopsy and surgery specimens obtained during the SOT follow-up period post PSMA PET will be analyzed for histopathology at the local laboratory, and for PSMA expression by IHC at a central laboratory.

    Time frame: At 3 months and 6 months post-piflufolastat F 18 administration

  3. Exploratory - Correlate circulating tumor DNA (ctDNA) levels and tumor specific genetic signatures with tumor burden assessed by piflufolastat F 18 PET imaging and PSMA IHC

    ctDNA sequencing will be performed to assess ctDNA levels and tumor-specific genetic signatures which may be correlated with piflufolastat F 18 PET/CT and PSMA IHC

    Time frame: At the time surgical/biopsy samples are obtained

  4. Exploratory - Compare piflufolastat F 18 PET/CT findings with PSMA expression levels in metastatic lesions as assessed using IHC

    Correlation of piflufolastat F 18 uptake parameters (including, but not limited to SUV peak, SUV mean, SUV max) and PSMA expression levels in metastatic lesions determined by IHC will be calculated.

    Time frame: Prior to piflufolastat F 18 dosing through surgical/biopsy sampling

  5. Exploratory - To Determine Positive Predictive Value (PPV)

    Positive Predictive Value (PPV) of piflufolastat F 18 PET/CT in the detection of metastatic ccRCC at a lesion level

    Time frame: From Day 1 (day of injection) where Piflufolastat F18 will be administered to 6 months post-piflufolastat F 18 administration

  6. Exploratory - utility of aPROMISE in patients with metastatic ccRCC

    PSMA score, number of lesions, and SUV values will be calculated using aPROMISE to generate quantification of disease burden in patients with metastatic ccRCC

    Time frame: From Day 1 (day of injection) where Piflufolastat F18 will be administered to 6 months post-piflufolastat F 18 administration

  7. Exploratory - Compare aPROMISE assessment with PSMA expression

    Correlation of aPROMISE results and PSMA expression in metastatic lesions assessed using IHC

    Time frame: From Day 1 (day of injection) where Piflufolastat F18 will be administered to 6 months post-piflufolastat F 18 administration

07

Study locations

2 sites
  • Washington University in St. Louis
    St Louis, Missouri 63130, United States
  • XCancer
    Omaha, Nebraska 68130, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Sep 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jul 25, 2025
StartEst.
Nov 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07084909
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Nov 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Dec 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piflufolastat

Start the discussion